RRML - Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon-β treatment in multiple sclerosis patients
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17


Advanced search


Top 10 downloaded articles
- January 2023 -
 
Romanian Review of Laboratory ... 16
Setting up an own laboratory p... 13
High DNAJA4 expression correla... 12
Downregulation of hsa-miR-4328... 11
Normality assessment, few para... 11
Invasive aspergillosis in hema... 10
Making the most out of profici... 9
Vitamin K and bone metabolism... 8
Oxidative stress and metabolic... 8
Spontaneous atrial fibrillatio... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 18(3)/2010
XML
TXT

Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon-β treatment in multiple sclerosis patients

Rodica Bălaşa, Adina Huţanu, Camelia Feier, Zoltan Bajko, Ion Pascu


Abstract:

Purpose: During interferon (IFNβ) treatment of multiple sclerosis (MS), the therapy induced binding antibodies (BAbs) and neutralizing antibodies might decrease the clinical efficacy of IFNβ. We evaluated: differences in immunogenicity of different IFNβ products using BAbs; the impact of BAbs on clinical efficacy of INFβ. We present the first Romanian experience on this issue. Material and methods: 229 MS patients treated for at least 12 months with either subcutaneous IFNβ-1b 250μg every other day (Betaferon 132 patients), subcutaneous IFNβ-1a 44μg three times a week (Rebif 71patients) or intramuscular IFNβ-1a 30μg once weekly (Avonex, 26 patients) were tested for BAbs using quantitative dELISA. The groups were clinically and demographically alike. According to the results, each group was divided into: 1.BAbs+; 2.BAbs-. Subgroups and titer of BAbs were compared with disability score (EDSS) variation in the last year and number of relapses during IFNβ treatment (Mann-Whitney and Spearman correlation). Results: The percentage of BAbs+ patients was: Betaferon 64.4%, Rebif 18.3%, Avonex 15.4%. In the Rebif group, a correlation was found between presence and value of BAbs and EDSS change (p=0.05) but not with the number of relapses. No correlation was found between the presence or value of BAbs and relapses or EDSS change in Betaferon or Avonex group. Conclusions: (i) Betaferon is more immunogenic than Rebif or Avonex; (ii) BAbs do not abrogate the clinical effects of Betaferon or Avonex regardless the parameter used; (iii) assays for BAbs are relatively inexpensive and have a role in following Rebif treatment.

Keywords: binding antibodies,neutralizing antibodies,multiple sclerosis,immunomodulatory treatment

 
  PDF Download full text PDF
(191 KB)
     
 
How to cite
Bălaşa R, Huţanu A, Feier C, Bajko Z, Pascu I. Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon-β treatment in multiple sclerosis patients. Rev Romana Med Lab. 2010;18(3):39-50